These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 11173124

  • 21. Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF.
    Girgert R, Wittrock J, Pfister S, Schweizer P.
    J Cancer Res Clin Oncol; 2003 Apr; 129(4):227-33. PubMed ID: 12700894
    [Abstract] [Full Text] [Related]

  • 22. Comparison of potential markers of farnesyltransferase inhibition.
    Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH.
    Clin Cancer Res; 2000 Jun; 6(6):2318-25. PubMed ID: 10873082
    [Abstract] [Full Text] [Related]

  • 23. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 25. Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models.
    Liu M, Bishop WR, Nielsen LL, Bryant MS, Kirschmeier P.
    Methods Enzymol; 2001 Sep; 333():306-18. PubMed ID: 11400347
    [Abstract] [Full Text] [Related]

  • 26. Ras inhibitors and radiation therapy.
    Jones HA, Hahn SM, Bernhard E, McKenna WG.
    Semin Radiat Oncol; 2001 Oct; 11(4):328-37. PubMed ID: 11677657
    [Abstract] [Full Text] [Related]

  • 27. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.
    Harari PM, Huang SM.
    Int J Radiat Oncol Biol Phys; 2001 Feb 01; 49(2):427-33. PubMed ID: 11173137
    [Abstract] [Full Text] [Related]

  • 28. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM.
    Oncogene; 2000 Nov 16; 19(48):5525-33. PubMed ID: 11114730
    [Abstract] [Full Text] [Related]

  • 29. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
    Shulman LN, Buswell L, Riese N, Doherty N, Loeffler JS, von Roemeling RW, Coleman CN.
    Int J Radiat Oncol Biol Phys; 1999 May 01; 44(2):349-53. PubMed ID: 10760430
    [Abstract] [Full Text] [Related]

  • 30. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
    Mazzocca A, Giusti S, Hamilton AD, Sebti SM, Pantaleo P, Carloni V.
    Mol Pharmacol; 2003 Jan 01; 63(1):159-66. PubMed ID: 12488548
    [Abstract] [Full Text] [Related]

  • 31. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
    Vordermark D, Brown JM.
    Strahlenther Onkol; 2003 Dec 01; 179(12):801-11. PubMed ID: 14652668
    [Abstract] [Full Text] [Related]

  • 32. [Biomodulation and radiotherapy].
    Bourhis J, Lartigau E.
    Cancer Radiother; 2000 Nov 01; 4 Suppl 1():128s-133s. PubMed ID: 11194950
    [Abstract] [Full Text] [Related]

  • 33. Chemical radiosensitizers for use in radiotherapy.
    Wardman P.
    Clin Oncol (R Coll Radiol); 2007 Aug 01; 19(6):397-417. PubMed ID: 17478086
    [Abstract] [Full Text] [Related]

  • 34. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC.
    Oncogene; 2003 Feb 27; 22(8):1124-34. PubMed ID: 12606940
    [Abstract] [Full Text] [Related]

  • 35. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
    Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N.
    Proc Natl Acad Sci U S A; 1998 Feb 17; 95(4):1369-74. PubMed ID: 9465021
    [Abstract] [Full Text] [Related]

  • 36. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ, Guitton JD, Baudoin B, Lelièvre Y, Duchesne M, Parker F, Fromage N, Commerçon A.
    J Med Chem; 1997 Jun 06; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract] [Full Text] [Related]

  • 37. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 38. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
    Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ.
    Cancer Res; 2003 Sep 15; 63(18):5656-68. PubMed ID: 14522880
    [Abstract] [Full Text] [Related]

  • 39. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K, Hamilton AD, Sebti SM.
    Curr Opin Investig Drugs; 2003 Dec 15; 4(12):1428-35. PubMed ID: 14763128
    [Abstract] [Full Text] [Related]

  • 40. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME, Gopal-Truter S, Seeburger G, Bhimnathwala H, Abrams MT, Davide JP, Ellis MS, Gibbs JB, Greenberg I, Koblan KS, Kral AM, Liu D, Lobell RB, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Senderak ET, Oliff A, Kohl NE.
    Cancer Res; 2000 May 15; 60(10):2680-8. PubMed ID: 10825141
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.